Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18431262 | COMBINATION THERAPY FOR TREATING CANCER | February 2024 | May 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18372398 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | September 2023 | January 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18372495 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | September 2023 | January 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18185268 | TREATMENT OF LOW-GRADE GLIOMA WITH MIRDAMETINIB | March 2023 | January 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18177073 | 18-MC SALT FORMS | March 2023 | January 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18057738 | Pyrazolo Compounds and Methods of Use Thereof | November 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 18056877 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | November 2022 | September 2024 | Abandon | 22 | 2 | 0 | No | No |
| 18056717 | SALT AND SOLID FORMS OF TABERNANTHALOG | November 2022 | April 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17983971 | Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators | November 2022 | May 2024 | Allow | 18 | 2 | 1 | No | No |
| 17970938 | Phytol-based surfactants and methods therefor | October 2022 | June 2024 | Allow | 20 | 2 | 0 | No | No |
| 18045210 | RADIATION-ACTIVATABLE PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC USE | October 2022 | June 2024 | Allow | 20 | 2 | 0 | No | No |
| 17934769 | NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | September 2022 | March 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17940984 | PREPARATION METHOD OF TOFACITINIB CITRATE | September 2022 | September 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17902795 | USES OF CORYLIN AND/OR NEOBAVAISOFLAVONE IN TREATING SYMPTOMS ASSOCIATED WITH SENESCENCE | September 2022 | December 2024 | Abandon | 27 | 4 | 0 | No | No |
| 17892651 | COMBINATION THERAPY FOR TREATING CANCER | August 2022 | May 2024 | Abandon | 20 | 1 | 1 | No | No |
| 17866008 | METHODS OF USING SUBSTITUTED FLAVONES FOR TREATING BONE DISORDERS | July 2022 | March 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17793275 | CRYSTAL FORM OF POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR | July 2022 | June 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17860599 | Dermatological Compositions and Methods of Treatment against Cutaneous T-Cell Lymphoma | July 2022 | July 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17857970 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION | July 2022 | April 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17855823 | PREPARATION AND APPLICATION OF TRITERPENOIDS WITH EFFECT OF IMPROVING GLUCOSE AND LIPID METABOLISM DISORDERS | July 2022 | March 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17854685 | MULTI-FUNCTIONAL NANOPARTICLE TARGETED TO BREAST CANCER, PREPARATION METHOD AND USE THEREOF | June 2022 | May 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17838171 | DUAL TREATMENT OF MIGRAINE | June 2022 | July 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17775795 | NOVEL SALT OF TERPHENYL COMPOUND | May 2022 | May 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17733419 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | April 2022 | May 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17732124 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | April 2022 | April 2025 | Allow | 36 | 2 | 1 | No | No |
| 17730764 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | April 2022 | June 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17703891 | PREPARATION OF GHRELIN O-ACYLTRANSFERASE INHIBITORS | March 2022 | February 2025 | Allow | 35 | 0 | 0 | No | No |
| 17700063 | COMBINATIONAL THERAPIES FOR TREATMENT OF CANCER COMPRISING A BACTERIOCHLOROPHYLL DERIVATIVE | March 2022 | November 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17627946 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | January 2022 | May 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17617011 | METHOD FOR TREATMENT OF AT RISK PATIENTS | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17596227 | POLYMORPH OF CDK9 INHIBITOR AND PREPARATION METHOD FOR POLYMORPH AND USE THEREOF | December 2021 | March 2025 | Allow | 39 | 1 | 0 | No | No |
| 17542540 | NOVEL ESTERS OF MEDROXYPROGESTERONE | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17615369 | COMPOSITION FOR CASPASE INHIBITOR PRODRUG INJECTION | November 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17610368 | METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS | November 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17606998 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | October 2021 | February 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17510050 | Treating Y537S Mutant Breast Cancer with RAD1901 and mTOR inhibitor | October 2021 | August 2023 | Allow | 22 | 2 | 0 | Yes | No |
| 17509238 | SYSTEMS AND METHODS FOR TREATMENTS OF AN EYE WITH A PHOTOSENSITIZER | October 2021 | September 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17599847 | PRODUCTION METHOD FOR RARE FATTY ACID USING NOVEL ENZYME, AND NOVEL RARE FATTY ACID | September 2021 | April 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17599338 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | September 2021 | March 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17598611 | SYNTHESIS AND APPLICATION OF DILTIAZEM HYDROCHLORIDE | September 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17439630 | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND �-THALASSEMIA | September 2021 | December 2024 | Allow | 39 | 1 | 0 | No | No |
| 17438753 | CRYSTAL FORM E OF BULLEYACONITINE A, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | September 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17437030 | 1-PYRIDYL-PYRAZOLYL AMIDE COMPOUNDS AND PREPARATION AND USES THEREOF | September 2021 | May 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17412851 | DIETARY SUPPLEMENT FORMULATED BASED ON ALL-TRANS FORM OF MENAQUINONE-7 | August 2021 | April 2024 | Abandon | 32 | 3 | 1 | No | No |
| 17425810 | MEDICAMENT FOR PROPHYLAXIS OR TREATMENT OF PULMONARY FIBROSIS | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17423745 | CRYSTALLINE FORMS OR AMORPHOUS FORMS OF N-(PHENYL SULFONYL) BENZAMIDE COMPOUNDS OR ITS SALTS OR SOLVATES | July 2021 | March 2025 | Allow | 44 | 2 | 0 | No | No |
| 17416711 | CYCLIN-DEPENDENT KINASE INHIBITORS | June 2021 | May 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17413327 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17413185 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17295721 | AN AURORA A KINASE INHIBITOR FOR USE IN THE TREATMENT OF NEUROBLASTOMA | May 2021 | August 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17292863 | FORMULATIONS OF INFLUENZA THERAPEUTICS | May 2021 | July 2024 | Allow | 38 | 1 | 0 | No | No |
| 17313955 | EPINEPHRINE SPRAY FORMULATIONS | May 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17291273 | MONOBACTAM COMPOUNDS AND USE THEREFOR | May 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17289122 | METHOD OF TREATMENT OF P53 WT TUMORS | April 2021 | June 2024 | Allow | 38 | 1 | 0 | No | No |
| 17309098 | METHODS AND TREATMENTS FOR ERECTILE DYSFUNCTION | April 2021 | March 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17287914 | SMALL MOLECULE VACCINE ADJUVANT FOR ENHANCING OR PROLONGING IMMUNE RESPONSE | April 2021 | May 2024 | Allow | 36 | 2 | 0 | No | No |
| 17236687 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | April 2021 | August 2024 | Allow | 39 | 1 | 0 | No | No |
| 17285485 | SOLID DISPERSION OF RIFAMYCIN-NITROIMIDAZOLE COUPLING MOLECULE AND APPLICATION THEREOF | April 2021 | May 2025 | Abandon | 49 | 3 | 0 | No | No |
| 17284369 | TRPV4 ACTIVITY INHIBITOR | April 2021 | May 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17282860 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | April 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17279694 | USE OF HISTIDINE, GLYCINE AND OTHER AMINO ACIDS FOR PREVENTING INSULIN RESISTANCE AND/OR DIABETES | March 2021 | November 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17275177 | Combination of Palbociclib and Adagrasib for Lung Cancer | March 2021 | August 2024 | Allow | 41 | 4 | 0 | No | No |
| 17275079 | SYNERGIC PHARMACEUTICAL COMBINATION OF A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 AND AN ANTHRAQUINONE DERIVATIVE | March 2021 | August 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17274136 | IMIDAZOQUINOLINE COMPOUNDS AND USES THEREOF | March 2021 | February 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17192083 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | March 2021 | May 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17271410 | SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF | February 2021 | May 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17271279 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENT AND GASTRIC ACID SECRETION INHIBITOR | February 2021 | June 2024 | Allow | 40 | 1 | 0 | No | No |
| 17182387 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | February 2021 | May 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17181043 | ACID ADDITION SALTS OF APOMORPHINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | February 2021 | April 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17265844 | SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS | February 2021 | June 2025 | Abandon | 53 | 2 | 0 | No | Yes |
| 17265678 | METHOD FOR HYDRATING LYOPHILIZED CYCLOPHOSPHAMIDE COMPOSITION AND PRODUCT THEREOF | February 2021 | June 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17264134 | SYNERGISTICALLY COOPERATIVE COMPOSITIONS USEFUL FOR SOFT TISSUE AUGMENTATION, DRUG DELIVERY AND RELATED FIELDS | January 2021 | November 2024 | Allow | 46 | 3 | 0 | No | No |
| 17262784 | METHODS OF ACTIVATING MICROGLIAL CELLS | January 2021 | August 2024 | Abandon | 43 | 2 | 1 | No | No |
| 17263126 | ANTI-BIOFILM COMPOUNDS | January 2021 | September 2024 | Allow | 44 | 1 | 1 | No | No |
| 17153333 | COMPOSITIONS FOR CYP450 PHENOTYPING USING SALIVA SAMPLES | January 2021 | August 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17148327 | Purified Detomidine, Process of Preparing and Methods of Use | January 2021 | April 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17258273 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | January 2021 | June 2024 | Allow | 41 | 2 | 0 | No | No |
| 17257917 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | January 2021 | March 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17085365 | Fatty Acid Synthase Inhibitor and Application Thereof | October 2020 | December 2023 | Allow | 38 | 1 | 0 | No | No |
| 17006601 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS | August 2020 | April 2025 | Abandon | 56 | 8 | 1 | No | No |
| 16696092 | Methods Of Treating Follicular Lymphoma | November 2019 | October 2024 | Abandon | 59 | 6 | 0 | No | No |
| 16441497 | FORMULATIONS/COMPOSITIONS COMPRISING IBRUTINIB | June 2019 | September 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16468756 | PARENTERAL LIQUID PREPARATION COMPRISING CARBAMATE COMPOUND | June 2019 | April 2024 | Allow | 58 | 6 | 1 | Yes | Yes |
| 16323110 | METHOD FOR THE MANAGEMENT OF DYSMENORRHEA AND MENSTRUAL PAIN | February 2019 | March 2025 | Abandon | 60 | 10 | 1 | Yes | No |
| 15514155 | PHARMACEUTICAL PREPARATION | March 2017 | March 2024 | Abandon | 60 | 7 | 1 | Yes | No |
| 15253010 | STABLE CANNABINOID FORMULATIONS | August 2016 | March 2025 | Abandon | 60 | 6 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAHLIN, HEATHER RAQUEL.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DAHLIN, HEATHER RAQUEL works in Art Unit 1629 and has examined 85 patent applications in our dataset. With an allowance rate of 37.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner DAHLIN, HEATHER RAQUEL's allowance rate of 37.6% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DAHLIN, HEATHER RAQUEL receive 1.82 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DAHLIN, HEATHER RAQUEL is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +59.5% benefit to allowance rate for applications examined by DAHLIN, HEATHER RAQUEL. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 12.0% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.0% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.